Shuttle Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Shuttle Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06359379
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath